Revolution Medicines (NASDAQ:RVMD) Earns "Sell (D-)" Rating from Weiss Ratings

Key Points

• Revolution Medicines received a "Sell (D-)" rating from Weiss Ratings, indicating concerns about the stock's performance.
• Despite the negative rating from Weiss, other analysts have given it a mix of ratings, including a "Strong Buy" and target prices as high as $80.00.
• The company's stock has shown significant volatility, with a 12-month low of $29.17 and a high of $62.40, currently trading around $47.82.

Revolution Medicines (NASDAQ:RVMD - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by stock analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Several other equities analysts also recently issued reports on RVMD. Raymond James Financial assumed coverage on Revolution Medicines in a research report on Friday, September 12th. They issued a "strong-buy" rating and a $72.00 target price on the stock. Piper Sandler assumed coverage on Revolution Medicines in a research report on Monday, August 18th. They issued an "overweight" rating and a $75.00 target price on the stock. Guggenheim reissued a "buy" rating and issued a $80.00 target price on shares of Revolution Medicines in a research report on Wednesday, June 25th. The Goldman Sachs Group upped their target price on Revolution Medicines from $65.00 to $73.00 and gave the company a "buy" rating in a research report on Friday, September 12th. Finally, Wedbush upped their target price on Revolution Medicines from $73.00 to $77.00 and gave the company an "outperform" rating in a research report on Thursday, September 11th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $74.64.

Revolution Medicines Stock Performance

Shares of RVMD opened at $47.82 on Wednesday. Revolution Medicines has a 12 month low of $29.17 and a 12 month high of $62.40. The stock has a fifty day moving average price of $40.61 and a 200-day moving average price of $38.97. The company has a current ratio of 11.79, a quick ratio of 11.79 and a debt-to-equity ratio of 0.13. The firm has a market cap of $8.94 billion, a PE ratio of -10.63 and a beta of 1.27.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.37). During the same quarter in the previous year, the firm posted ($0.81) earnings per share. The company's quarterly revenue was up .0% on a year-over-year basis. Equities research analysts predict that Revolution Medicines will post -3.49 earnings per share for the current fiscal year.

Insider Activity at Revolution Medicines

In other Revolution Medicines news, insider Mark A. Goldsmith sold 13,411 shares of the stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $45.82, for a total transaction of $614,492.02. Following the sale, the insider directly owned 452,309 shares of the company's stock, valued at approximately $20,724,798.38. This trade represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Margaret A. Horn sold 4,775 shares of the stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $45.82, for a total value of $218,790.50. Following the sale, the chief operating officer directly owned 145,900 shares in the company, valued at $6,685,138. This represents a 3.17% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 163,033 shares of company stock worth $7,242,708 in the last three months. Company insiders own 8.20% of the company's stock.

Institutional Investors Weigh In On Revolution Medicines

Several hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. boosted its stake in shares of Revolution Medicines by 2.1% during the 1st quarter. Principal Financial Group Inc. now owns 12,792 shares of the company's stock worth $452,000 after acquiring an additional 259 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Revolution Medicines by 45.1% during the 3rd quarter. GAMMA Investing LLC now owns 837 shares of the company's stock worth $39,000 after acquiring an additional 260 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of Revolution Medicines by 0.3% during the 2nd quarter. California State Teachers Retirement System now owns 140,077 shares of the company's stock worth $5,153,000 after acquiring an additional 437 shares in the last quarter. CWM LLC boosted its stake in shares of Revolution Medicines by 171.3% during the 2nd quarter. CWM LLC now owns 917 shares of the company's stock worth $34,000 after acquiring an additional 579 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Revolution Medicines by 11.0% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,221 shares of the company's stock worth $232,000 after acquiring an additional 615 shares in the last quarter. 94.34% of the stock is owned by hedge funds and other institutional investors.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.